Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$69.2K Buy
802
+150
+23% +$12.5K ﹤0.01% 1407
2026
Q2
$43.9K Buy
652
+257
+65% +$17.1K ﹤0.01% 1620
2026
Q1
$24.8K Sell
395
-7
-2% -$487 ﹤0.01% 1620
2025
Q4
$26.7K Buy
402
+96
+31% +$6.21K ﹤0.01% 1616
2025
Q3
$20.6K Hold
306
– – ﹤0.01% 1563
2025
Q2
$26.7K Sell
306
-110
-26% -$8.62K ﹤0.01% 1377
2025
Q1
$28.4K Buy
416
+48
+13% +$3.92K ﹤0.01% 1321
2024
Q4
$28.6K Sell
368
-70
-16% -$5.18K ﹤0.01% 1322
2024
Q3
$29.4K Buy
+438
New +$36K ﹤0.01% 1289

Other funds holding DXCM

BFC Planning's DXCM Position: Q3 2026 in Review

BFC Planning increased its DexCom (DXCM) stake by 23% in Q3 2026, buying an estimated $12.5K and bringing the position to 802 shares worth $69.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

BFC Planning first reported a position in DXCM in Q3 2024 and has held it in 9 quarters since. 884 funds tracked by Wall St. Rank hold DXCM as of Q3 2026.

  • BFC Planning held 802 shares of DexCom worth $69.2K as of Q3 2026.
  • BFC Planning bought 150 DexCom shares in Q3 2026, an estimated $12.5K.
  • DexCom made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #1407 holding.
  • BFC Planning first reported a position in DexCom in Q3 2024 and has held it in 9 quarters since.
  • 884 funds tracked by Wall St. Rank held DexCom as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.